XLenti™ Stable Cell Lines for Lentivirus Manufacturing: new development, characterisation, and future goals
Lentiviral vectors (LV) present huge potential for cell and gene therapy. After the first LV-engineered CAR-T cell therapies gained approval by the FDA in 2017 (Yescarta and Kymriah), more LV-based therapies are being investigated and more than 600 trials are active in the US. The demand for more efficient LV manufacturing continues to increase, but the technology still presents challenges associated with process robustness and scalability, as well as high cost-of-goods.
Download the resource to continue reading.